Your browser doesn't support javascript.
loading
Mending the Gap: AlloDerm as a Safe and Effective Option for Vaginal Canal Lining in Revision Robotic Assisted Gender Affirming Peritoneal Flap Vaginoplasty.
Parker, Augustus; Brydges, Hilliard; Blasdel, Gaines; Bluebond-Langner, Rachel; Zhao, Lee C.
Affiliation
  • Parker A; NYU Grossman School of Medicine, New York, NY.
  • Brydges H; Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY.
  • Blasdel G; Department of Urology, NYU Langone Health, New York, NY; University of Michigan Medical School, Ann Arbor, MI.
  • Bluebond-Langner R; Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY.
  • Zhao LC; Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY; Department of Urology, NYU Langone Health, New York, NY. Electronic address: Lee.zhao@nyulangone.org.
Urology ; 173: 204-208, 2023 03.
Article in En | MEDLINE | ID: mdl-36642117
ABSTRACT

OBJECTIVE:

To address instances when there is insufficient remnant tissue to perform revision following canal-deepening gender affirming vaginoplasty revisions as indicated by insufficient depth. Options for lining of the vaginal canal include skin grafts, peritoneal flaps, or intestinal segment. Our center uses robotically harvested peritoneal flaps in vaginal canal revisions. When the peritoneal flap is insufficient for full canal coverage, we use AlloDerm, an acellular dermal matrix, for additional coverage.

METHODS:

Retrospective analysis of 9 patients who underwent revision RPV with AlloDerm was performed. Tubularized AlloDerm grafts were used to connect remnant vaginal lining to the peritoneal flaps. Revision indications, surgical and patient outcomes, and patient-reported post-op dilation were recorded.

RESULTS:

Nine patients underwent revision RPV using AlloDerm for canal deepening. Median follow-up was 368 days (Range 186-550). Following revision, median depth and width at last follow-up were 12.1 cm and 3.5 cm, and median increase in depth and width were 9.7 cm and 0.9 cm, respectively. There were no intraoperative complications. Two patients had focal areas of excess AlloDerm that were treated with in-office excision without compromise of the caliber or depth of the otherwise healed, epithelialized canal.

CONCLUSION:

AlloDerm is an off-the-shelf option that does not require a secondary donor site. The use of AlloDerm for a pilot cohort of patients lacking sufficient autologous tissue for revision RPV alone was demonstrated to be safe and effective at a median 1-year follow-up.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Robotic Surgical Procedures Type of study: Observational_studies Aspects: Determinantes_sociais_saude Limits: Female / Humans Language: En Journal: Urology Year: 2023 Document type: Article Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Robotic Surgical Procedures Type of study: Observational_studies Aspects: Determinantes_sociais_saude Limits: Female / Humans Language: En Journal: Urology Year: 2023 Document type: Article Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA